Comparative Pharmacology
Head-to-head clinical analysis: GRISACTIN versus HALOTEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRISACTIN versus HALOTEX.
GRISACTIN vs HALOTEX
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Binds to microtubules and disrupts mitotic spindle formation, inhibiting fungal cell division.
Halotex (haloprogin) is a topical antifungal agent that disrupts fungal cell membrane permeability and inhibits ergosterol synthesis, leading to cell death.
Tinea capitisTinea corporisTinea crurisTinea pedisTinea unguium (onychomycosis) caused by Trichophyton, Microsporum, and Epidermophyton species
Treatment of tinea pedis (athlete's foot), tinea cruris (jock itch), tinea corporis (ringworm), tinea manuum, and tinea versicolor caused by susceptible fungi such as Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Malassezia furfur.
500 mg orally once daily or 250 mg orally twice daily for dermatophyte infections.
Apply topically twice daily for 2-4 weeks; tinea pedis may require up to 6 weeks.
None Documented
None Documented
Terminal elimination half-life: 9–24 hours (mean ~14 hours). Clinical context: Steady-state achieved in 3–5 days; once-daily dosing is effective due to prolonged half-life.
Not well characterized; estimated terminal half-life approximately 24-48 hours based on limited data.
Hepatic metabolism via N-demethylation and glucuronidation; primarily metabolized by CYP450 enzymes.
Haloprogin is primarily metabolized in the liver via oxidation and conjugation, with minimal systemic absorption following topical application.
Renal: <1% as intact drug; fecal: >99% as metabolites (mainly 6-demethylgriseofulvin glucuronide) via bile; negligible biliary excretion of parent compound.
Primarily fecal (biliary) as unchanged drug and metabolites; negligible renal excretion (<1%).
Extensively bound to plasma proteins (>97%), primarily to albumin and possibly other proteins.
Approximately 99% bound to plasma proteins, primarily albumin.
Apparent Vd: 0.25–0.58 L/kg. Indicates distribution into total body water and deep tissue compartments (e.g., skin, hair, nails, liver, fat). Accumulates in keratin precursor cells.
Not established; likely low due to high protein binding and lipophilicity.
Oral bioavailability is variable (approximately 50% for micronized formulation; ultra-microsized formulation ~100% relative to micronized). GRISACTIN is micronized; absorption enhanced by fatty meal.
Topical: negligible systemic absorption (<0.5% of applied dose); oral: not available.
No dose adjustment required for renal impairment; griseofulvin is not significantly renally eliminated.
No adjustment needed; topical use with minimal systemic absorption.
Contraindicated in severe hepatic impairment (Child-Pugh class C). In mild-moderate impairment, use with caution; no specific dose adjustment guidelines available.
No adjustment needed; topical use with minimal systemic absorption.
Children >2 years: 10-20 mg/kg/day orally in divided doses (single or twice daily). Maximum 500 mg/day.
Safety not established; use only if clearly needed.
No specific dose adjustment; monitor for adverse effects and drug interactions due to potential polypharmacy and age-related physiological changes.
No specific adjustments; monitor for irritation.
No FDA black box warning.
No FDA black box warning.
["Monitor liver function tests; hepatotoxicity possible","May exacerbate porphyria","Monitor for hypersensitivity reactions","Use cautiously in patients with penicillin allergy (potential cross-sensitivity)"]
For external use only. Avoid contact with eyes and mucous membranes. Discontinue if irritation or sensitization occurs. Use with caution in patients with known hypersensitivity to haloprogin or any component of the formulation.
["Hypersensitivity to griseofulvin","Porphyria","Hepatic failure","Pregnancy (teratogenic)"]
Hypersensitivity to haloprogin or any component of the formulation.
Data Pending Review
Data Pending Review
High-fat meals significantly increase absorption of griseofulvin. Avoid alcohol during therapy due to possible disulfiram-like reaction (tachycardia, flushing).
No known food interactions. Topical use minimizes systemic absorption.
GRISACTIN (griseofulvin) is teratogenic in animals; in humans, first trimester exposure is associated with increased risk of conjoined twins and other malformations (limited data). Avoid use during pregnancy; particularly contraindicated in first trimester. Risk in second and third trimesters is unknown but manufacturer advises avoidance.
Haloprogin (HALOTEX) is a topical antifungal. Systemic absorption is minimal, and no teratogenic effects have been reported in animal studies. There are no adequate well-controlled studies in pregnant women. Risk to the fetus is considered low when applied topically as directed.
Griseofulvin is excreted into breast milk; milk-to-plasma ratio approximately 0.5. Potential for adverse effects in nursing infant (e.g., hepatotoxicity, carcinogenicity). Contraindicated during breastfeeding; alternative antifungal therapy recommended.
It is not known whether haloprogin is excreted in human milk. Because of minimal systemic absorption, risk to nursing infant is likely low. Caution is advised. M/P ratio not available.
No established dosing adjustments for pregnancy; use is contraindicated. Griseofulvin is metabolized by liver; pregnancy may alter clearance but specific data are lacking. Do not use in pregnant women; consider alternative antifungals with better safety profile.
No dosage adjustment is necessary during pregnancy due to minimal systemic absorption and lack of pharmacokinetic studies indicating changes.
Category C
Category C
GRISACTIN (griseofulvin) is a fungistatic antibiotic used for dermatophyte infections. It is most effective against Trichophyton, Microsporum, and Epidermophyton species. Administer with a high-fat meal to enhance absorption. Monitor for hepatotoxicity, especially in patients with pre-existing liver disease. It induces CYP450 enzymes, potentially reducing efficacy of oral contraceptives and warfarin. Avoid use in porphyria. Duration of therapy may be several weeks to months. Interaction with alcohol may cause tachycardia and flushing.
HALOTEX (haloprogin) is a topical antifungal for dermatophyte and Candida infections. Apply to affected area twice daily for 2-4 weeks post-resolution to prevent recurrence. Avoid occlusive dressings unless directed. Not for nail or scalp use.
Take GRISACTIN with food, especially fatty foods, to improve absorption.Complete the full course of treatment even if symptoms improve.Avoid alcohol while taking this medication due to risk of rapid heart rate and flushing.Use additional contraceptive measures if on oral contraceptives; GRISACTIN may reduce their effectiveness.Report signs of liver problems: yellowing of skin/eyes, dark urine, severe nausea/vomiting.This medication may make your skin more sensitive to sunlight; use sunscreen and protective clothing.Do not take if you have porphyria.Keep out of reach of children and do not share with others.
Apply a thin layer to clean, dry skin twice daily.Continue use for at least 2 weeks after symptoms resolve to prevent recurrence.Do not cover treated areas with bandages or wraps unless instructed.Avoid contact with eyes, mouth, or mucous membranes.Report signs of irritation or allergic reaction (rash, burning, swelling).Do not use on nails or scalp; this medicine is for skin only.